SCHEMBL1391069

SCHEMBL1391069

O=Cc1ccc(CCc2ccc3c(c2)OCO3)cc1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CALM1 P0DP23 3/20 0.56
TDP1 Q9NUW8 2/20 0.52
KMT2A Q03164 2/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
TAAR1 Q96RJ0 1/20 0.51
HDAC1 Q13547 2/20 0.49
HDAC8 Q9BY41 1/20 0.49
CYP3A4 P08684 3/20 0.47
CYP1A2 P05177 2/20 0.47
ALDH1A1 P00352 2/20 0.47
CYP2C19 P33261 1/20 0.47
MAPT P10636 1/20 0.46
HSD17B10 Q99714 1/20 0.46
HDAC3 O15379 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
POLB P06746 1/20 0.46
MEN1 O00255 1/20 0.45
TRPM8 Q7Z2W7 1/20 0.45
INSR P06213 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8132974 0.82 L3MBTL1 (0.63) CALM1TDP1KMT2AL3MBTL1CYP3A4
SCHEMBL21002110 0.82 CDK1 (0.58) TDP1TAAR1ALDH1A1MAPTHSD17B10
Salicyladehyde SCHEMBL28996474 0.79 KMT2A (0.55) CALM1TDP1KMT2AL3MBTL1TAAR1
SCHEMBL1391559 0.79 ERN1 (0.58) POLB
SCHEMBL108087 0.79 TAAR1 (0.77) CALM1TAAR1CYP3A4CYP1A2ALDH1A1
SCHEMBL12432290 0.77 CDK1 (0.58) TDP1TAAR1ALDH1A1MAPTHSD17B10
SCHEMBL7923442 0.77 CALM1 (0.60) CALM1TAAR1HDAC1CYP3A4CYP1A2
SCHEMBL1390751 0.76 RARB (0.40) CALM1
SCHEMBL1391109 0.75 TDP1 (0.57) CALM1TDP1KMT2AL3MBTL1TAAR1
Hydrochloric Acid SCHEMBL27893084 0.75 TAAR1 (0.57) CALM1TDP1KMT2AL3MBTL1TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501804-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-08-06 US disclosed
US-8501804-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-08-06 US disclosed
US-8501804-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-08-06 US disclosed
US-20120010247-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-01-12 US disclosed
US-20120010247-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-01-12 US disclosed
US-20120010247-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-01-12 US disclosed
EP-2351743-A1 BICYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-08-03 EP disclosed
WO-2010050445-A1 BICYCLIC COMPOUND 武田薬品工業株式会社 (JP) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010247-A1 BICYCLIC COMPOUND ACACA, CPT1B, ACACB CALM1 724/4885TDP1 4400/4885KMT2A 1599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.